Pharmaceutical Technology

JULY 1, 2025

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

FDA

Roots Analysis

JANUARY 27, 2025

This also increases the cost of the treatment, in terms of both the cost of the prescribed therapeutic regimen and transportation / hospital cost ( due to numerous hospital visits and other healthcare costs ). Currently, antibodies segment is likely to occupy the largest share in the overall market.

Hospitals

Pharmaceutical Technology

JUNE 26, 2025

The study, which is expected to produce initial results in the first half of 2027, will support potential approval in the US and Europe. By GlobalData Learn more about Strategic Intelligence RemeGen is conducting a global Phase III clinical trial with telitacicept for the treatment of generalised myasthenia gravis.

Packaging

Pharmaceutical Technology

JUNE 19, 2025

Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Then the next step is to produce meaningful quantities of these crystals, which will be next year.” After that, it will be about compliance and regulation, as we must ensure that all our processes adhere to pharma regulations.

Communication

Pharmaceutical Technology

JULY 14, 2025

Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO’s overall budget for 2026-2027 will be lower than that for 2024-2025. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Vaccines

Pharmaceutical Technology

JULY 2, 2025

With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 29, 2025

Merck & Co (MSD) has joined fellow big pharma companies in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027. Pfizer and BMS both have programmes set to save $1.5bn and $2bn, respectively, by 2027. Credit: HJBC via Shutterstock. Sign up for our daily news round-up!

Packaging

Pharmaceutical Technology

AUGUST 5, 2025

The company said it is on track to deliver $7.2bn in net savings by the end of 2027 as rising costs hit drugmakers across the US and Europe. Pfizer is one of many companies undergoing cost-saving strategies. Moderna, MSD, and BMS also all have billion-dollar cost-cutting programmes planned or underway.

Vaccines

Pharmaceutical Technology

JULY 17, 2025

Find out more After its strategic review, the company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability. This approach should maintain access to a $600m revolving credit facility while managing liabilities proactively, including repayment of convertible notes due in 2027.

Labelling

Pharmaceutical Technology

JUNE 25, 2025

The European Commission (EC) faces a March 2027 deadline to adopt several key implementing acts, which will lay out detailed rules for putting the regulation into practice. In March 2031, secondary use data will be made available, including medical images, lab results, and hospital discharge reports.

Communication

PharmaShots

JULY 23, 2025

Given the prevalence of DLL3 overexpression across a variety of neuroendocrine tumors, at Zai we are continuing to advance a clear strategy to expand the reach of ZL-1310 across multiple high-need DLL3-expressing solid tumor types, with our first regulatory submission targeted in 2027.

Chemotherapy

pharmaphorum

NOVEMBER 25, 2020

Jefferies expects that the company expects sales of $14 billion could be at risk by 2027 from patent expiries of Tasigna, Promacta, Jakavi, Gilenya and Entresto. Uptake of biosimilars in the US has been better than hoped, perhaps aided by hospitals focusing on cost because COVID-19 has curtailed income from surgery.

Hospitals

STAT

JULY 24, 2023

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

Packaging

European Pharmaceutical Review

SEPTEMBER 21, 2023

A few hospitals in Denmark already have small-scale facilities for manufacturing products for these innovative treatments. The Novo Nordisk Foundation Cellerator is expected to be in operation in 2027. CGT manufacturing QC market to value $2.8b

Hospitals

STAT

JULY 25, 2023

The House Ways & Means Committee proposed a package that includes a new provision to ensure Medicare patients pay for medicines they pick up at pharmacies based on discounted prices insurers negotiate with drugmakers, instead of higher list prices, starting in 2027 , STAT reports.

Insurance

The deprescribing.org Blog

JUNE 2, 2023

falls, fractures, cognition problems, and hospitalizations). In Ontario, more than half of LTC residents with diabetes are treated too strictly (i.e. A1c < 7%). This puts residents at risk for harms like low blood sugar and its consequences (e.g.,

Hospitals

The Happy PharmD

SEPTEMBER 4, 2024

Did you know that the infusion pharmacy market is projected to reach $20 billion dollars by 2027? This flexibility extends to career transitions, allowing pharmacists to move between hospital settings, ambulatory care, and community pharmacy without extensive retraining.

Specialty Pharmacies

Pharmaceutical Technology

OCTOBER 13, 2022

According to AorticLab, 190,000 patients worldwide underwent TAVI procedures in 2020 and, with an ageing population, it predicts that by 2027 there could be 390,000 cases. This is an important benefit for the hospital. The TAVI procedure carries an inherent risk of stroke and of these, 50% are disabling.

Hospitals

Omnicell

JANUARY 10, 2023

Hospitals and health systems have long advocated for lower prescription drug prices. In March, in a statement to the Senate Finance Committee, the American Hospital Association contended that prescription drug price inflation constituted “an urgent need to lower drug prices in Medicare.”

Hospitals

Hospital Pharmacy Europe

SEPTEMBER 19, 2022

They set out to simulate heart disease and stroke events, mortality and health care costs between 2018 and 2027. The post Dietary changes provide greatest reduction in CVD events for stage 1 hypertensives appeared first on Hospital Pharmacy Europe. Adults Hypertension 2022.

Hospitals

Hospital Pharmacy Europe

NOVEMBER 23, 2023

The level of annual allowed growth in sales of branded medicines will double from 2% in 2024 to 4% by 2027. The post VPAG rebate calculations risk NHS medicines shortages, warns generics industry appeared first on Hospital Pharmacy Europe. Sales above the cap are paid back to the Government via a levy.

Hospitals

ISPE

SEPTEMBER 11, 2023

Fill Finish Manufacturing Market by Product (Consumables (Prefilled Syringes (Glass, Plastic), Vial (Glass), Cartridge), Instrument (System (Stand alone, Integrated), Machine Type (Automated, Manual))), End User (CMO, Biopharma) & Region - Global Forecast to 2027.” September 2022. 25%20from%202022%20to%202027 24 Eglovitch, J.

Health and Personal Care Stores

ISPE

MARCH 8, 2023

35 Cross-contamination involving vincristine also led to neurologic symptoms such as weakness and paralysis in at least 107 patients across 12 hospitals in China, despite investigations revealing that vincristine was only present in trace amounts between 0.28 and 18 micrograms per milliliter. 33 2 a b c d e f Bharate, S. Morikawa, M.

Compounding

Omnicell

SEPTEMBER 5, 2022

31, 2027) with a four-year phase-in period that incorporates a system of external reference pricing. The American Hospital Association (AHA) opposes the MFN Model, as it estimates that the model will result in an average 65 percent decrease in drug reimbursements to hospitals when it is fully phased in.

Omnicell

STAT

APRIL 18, 2025

Hospitals, health insurers, and insurance agents are asking President Trump to pump the brakes on a regulation that would lead to potentially millions of people losing their health insurance.

Insurance